The effect of trelagliptin on vascular endothelial functions in patients with type II diabetes mellitus.
Not Applicable
- Conditions
- Patients with type 2 diabetes
- Registration Number
- JPRN-UMIN000018311
- Lead Sponsor
- Ise Red Cross Hospital Department of Metabolic Diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) type 1 diabetes 2) secondary diabetes 3) Patients receiving insulin or GLP-1 analogue therapy 4) Poor-controlled diabetes (HbA1c>10.0 % or fasting blood glucose levels greater than 250mg/dl) 5) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 6) Either level of aspartate aminotransaminase or alanine aminotransferase exceed three-fold of the normal limits 7) renal insufficiency: serum creatinine>1.5 8) Malignancies or other diseases with poor prognosis 9) Pregnant 10) Subjects whose doctor in charge do not agree to join the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Flow mediated dilation (FMD)
- Secondary Outcome Measures
Name Time Method Hemoglobin A1C levels, pre/postprandial blood glucose/lipids levels, BMI, adiponectin, ADMA, mean IMT, mean ba-PWV